Whitfield Advises Curium on Merger with Lantheus

Press Release   ·   03 August 2026

Overview

Curium agreed to combine with Lantheus in a radiopharmaceutical transaction valued at up to approximately $8 billion, according to the source announcement.

Shareholder consideration

Lantheus holders would receive $102.50 cash per share plus non-transferable rights to potential additional payments totaling up to $12 per share.

Milestones and timetable

Additional consideration depended on commercial milestones through 2030. Closing was expected in the first half of 2027 after shareholder and regulatory approvals.

Named advisers

Rachael Coffey and Carlos Gil Rivas are among the corporate advisers credited, with separate debt finance and competition workstreams also listed.